GW&K Investment Management LLC Grows Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

GW&K Investment Management LLC lifted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 1.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 470,546 shares of the specialty pharmaceutical company's stock after acquiring an additional 6,543 shares during the quarter. GW&K Investment Management LLC owned approximately 0.76% of Jazz Pharmaceuticals worth $58,418,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Focus Partners Wealth acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth about $551,000. CX Institutional acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $4,316,000. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Jazz Pharmaceuticals by 38.9% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock valued at $542,000 after purchasing an additional 1,223 shares during the period. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 63.7% in the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after purchasing an additional 395 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $1,888,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $0.27 during trading on Thursday, reaching $117.61. 161,834 shares of the company traded hands, compared to its average volume of 973,599. The firm's fifty day simple moving average is $109.79 and its 200 day simple moving average is $118.13. The stock has a market cap of $7.12 billion, a P/E ratio of 15.68, a PEG ratio of 5.60 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm's revenue for the quarter was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.68 EPS. As a group, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JAZZ. Morgan Stanley dropped their price objective on Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Piper Sandler reaffirmed an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Robert W. Baird decreased their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $181.64.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan bought 100,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 9th. The shares were bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director directly owned 100,000 shares in the company, valued at $9,826,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer owned 439,307 shares in the company, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,500 shares of company stock worth $277,930 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.